MTOR and angiomyolipoma: Based on these results, the International Tuberous Sclerosis Complex Consensus Conference (ITSCCC) recommended the use of mammalian target of rapamycin (mTOR) inhibitors for first-line therapy for management of asymptomatic, growing angiomyolipomas >3 cm in diameter14.